<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33333772</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>24</Issue><PubDate><Year>2020</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Palmitoylethanolamide: A Nutritional Approach to Keep Neuroinflammation within Physiological Boundaries-A Systematic Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">9526</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms21249526</ELocationID><Abstract><AbstractText>Neuroinflammation is a physiological response aimed at maintaining the homodynamic balance and providing the body with the fundamental resource of adaptation to endogenous and exogenous stimuli. Although the response is initiated with protective purposes, the effect may be detrimental when not regulated. The physiological control of neuroinflammation is mainly achieved via regulatory mechanisms performed by particular cells of the immune system intimately associated with or within the nervous system and named "non-neuronal cells." In particular, mast cells (within the central nervous system and in the periphery) and microglia (at spinal and supraspinal level) are involved in this control, through a close functional relationship between them and neurons (either centrally, spinal, or peripherally located). Accordingly, neuroinflammation becomes a worsening factor in many disorders whenever the non-neuronal cell supervision is inadequate. It has been shown that the regulation of non-neuronal cells-and therefore the control of neuroinflammation-depends on the local "<i>on demand</i>" synthesis of the endogenous lipid amide Palmitoylethanolamide and related endocannabinoids. When the balance between synthesis and degradation of this bioactive lipid mediator is disrupted in favor of reduced synthesis and/or increased degradation, the behavior of non-neuronal cells may not be appropriately regulated and neuroinflammation exceeds the physiological boundaries. In these conditions, it has been demonstrated that the increase of endogenous Palmitoylethanolamide-either by decreasing its degradation or exogenous administration-is able to keep neuroinflammation within its physiological limits. In this review the large number of studies on the benefits derived from oral administration of micronized and highly bioavailable forms of Palmitoylethanolamide is discussed, with special reference to neuroinflammatory disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Petrosino</LastName><ForeName>Stefania</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Endocannabinoid Research Group, Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche, Via Campi Flegrei 34, 80078 Napoli, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Epitech Group SpA, Via Einaudi 13, 35030 Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schiano Moriello</LastName><ForeName>Aniello</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Endocannabinoid Research Group, Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche, Via Campi Flegrei 34, 80078 Napoli, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Epitech Group SpA, Via Einaudi 13, 35030 Padova, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000577">Amides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D063388">Endocannabinoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004983">Ethanolamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010169">Palmitic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>6R8T1UDM3V</RegistryNumber><NameOfSubstance UI="C005958">palmidrol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000178" MajorTopicYN="N">diet therapy</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000577" MajorTopicYN="N">Amides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000178" MajorTopicYN="N">diet therapy</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067877" MajorTopicYN="N">Autism Spectrum Disorder</DescriptorName><QualifierName UI="Q000178" MajorTopicYN="N">diet therapy</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063388" MajorTopicYN="N">Endocannabinoids</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004983" MajorTopicYN="N">Ethanolamines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000178" MajorTopicYN="Y">diet therapy</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053858" MajorTopicYN="N">Metabolic Networks and Pathways</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000178" MajorTopicYN="N">diet therapy</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="N">Nervous System Diseases</DescriptorName><QualifierName UI="Q000178" MajorTopicYN="N">diet therapy</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000178" MajorTopicYN="N">diet therapy</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName><QualifierName UI="Q000178" MajorTopicYN="N">diet therapy</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010169" MajorTopicYN="N">Palmitic Acids</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">dietary food</Keyword><Keyword MajorTopicYN="N">endocannabinoid system</Keyword><Keyword MajorTopicYN="N">mast cells</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword><Keyword MajorTopicYN="N">nutrient</Keyword><Keyword MajorTopicYN="N">palmitoylethanolamide</Keyword></KeywordList><CoiStatement>S.P. and A.S.M. are employees of Epitech Group SpA. Stefania Petrosino is a co-inventor on patent EP2965765A1 that is wholly unrelated to the present study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>18</Day><Hour>1</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33333772</ArticleId><ArticleId IdType="pmc">PMC7765232</ArticleId><ArticleId IdType="doi">10.3390/ijms21249526</ArticleId><ArticleId IdType="pii">ijms21249526</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Boche D., Perry V.H., Nicoll J.A.R. Review: Activation patterns of microglia and their identification in the human brain. Neuropathol. Appl. Neurobiol. 2013;39:3&#x2013;18. doi: 10.1111/nan.12011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12011</ArticleId><ArticleId IdType="pubmed">23252647</ArticleId></ArticleIdList></Reference><Reference><Citation>Bordon Y. Neuroinflammation: Inflammatory brain drain. Nat. Rev. Immunol. 2013;13:69. doi: 10.1038/nri3392.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3392</ArticleId><ArticleId IdType="pubmed">23334247</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren K., Dubner R. Interactions between the immune and nervous systems in pain. Nat. Med. 2010;16:1267&#x2013;1276. doi: 10.1038/nm.2234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2234</ArticleId><ArticleId IdType="pmc">PMC3077564</ArticleId><ArticleId IdType="pubmed">20948535</ArticleId></ArticleIdList></Reference><Reference><Citation>Sominsky L., Walker A.K., Hodgson D.M. Editorial: Neuroinflammation and behavior. Front. Neurosci. 2015;9:201. doi: 10.3389/fnins.2015.00201.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2015.00201</ArticleId><ArticleId IdType="pmc">PMC4451363</ArticleId><ArticleId IdType="pubmed">26082681</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelissen S., Lemmens E., Geurts N., Kramer P., Maurer M., Hendriks J., Hendrix S. The role of mast cells in neuroinflammation. Acta Neuropathol. 2013;125:637&#x2013;650. doi: 10.1007/s00401-013-1092-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1092-y</ArticleId><ArticleId IdType="pubmed">23404369</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong H., Zhang X., Qian Y. Mast cells and neuroinflammation. Med. Sci. Monit. Basic Res. 2014;20:200&#x2013;206. doi: 10.12659/MSMBR.893093.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSMBR.893093</ArticleId><ArticleId IdType="pmc">PMC4282993</ArticleId><ArticleId IdType="pubmed">25529562</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji R.-R., Xu Z.-Z., Gao Y.-J. Emerging targets in neuroinflammation-driven chronic pain. Nat. Rev. Drug Discov. 2014;13:533&#x2013;548. doi: 10.1038/nrd4334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd4334</ArticleId><ArticleId IdType="pmc">PMC4228377</ArticleId><ArticleId IdType="pubmed">24948120</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloyd D., Aon M.A., Cortassa S. Why Homeodynamics, Not Homeostasis? Sci. World J. 2001;1:918917. doi: 10.1100/tsw.2001.20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1100/tsw.2001.20</ArticleId><ArticleId IdType="pmc">PMC6084724</ArticleId><ArticleId IdType="pubmed">12805697</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchand F., Perretti M., McMahon S.B. Role of the immune system in chronic pain. Nat. Rev. Neurosci. 2005;6:521&#x2013;532. doi: 10.1038/nrn1700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn1700</ArticleId><ArticleId IdType="pubmed">15995723</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira R., Bernardino L. Dual role of microglia in health and disease: Pushing the balance toward repair. Front. Cell. Neurosci. 2015;9:51. doi: 10.3389/fncel.2015.00051.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2015.00051</ArticleId><ArticleId IdType="pmc">PMC4333815</ArticleId><ArticleId IdType="pubmed">25745386</ArticleId></ArticleIdList></Reference><Reference><Citation>Skaper S.D., Facci L., Giusti P. Neuroinflammation, microglia and mast cells in the pathophysiology of neurocognitive disorders: A review. CNS Neurol. Disord. Drug Targets. 2014;13:1654&#x2013;1666. doi: 10.2174/1871527313666141130224206.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871527313666141130224206</ArticleId><ArticleId IdType="pubmed">25470401</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocha S.M., Pires J., Esteves M., Gra&#xe7;a B., Bernardino L. Histamine: A new immunomodulatory player in the neuron-glia crosstalk. Front. Cell. Neurosci. 2014;8:120. doi: 10.3389/fncel.2014.00120.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00120</ArticleId><ArticleId IdType="pmc">PMC4012198</ArticleId><ArticleId IdType="pubmed">24817841</ArticleId></ArticleIdList></Reference><Reference><Citation>Caldeira C., Oliveira A.F., Cunha C., Vaz A.R., Falc&#xe3;o A.S., Fernandes A., Brites D. Microglia change from a reactive to an age-like phenotype with the time in culture. Front. Cell. Neurosci. 2014;8:152. doi: 10.3389/fncel.2014.00152.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00152</ArticleId><ArticleId IdType="pmc">PMC4040822</ArticleId><ArticleId IdType="pubmed">24917789</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendriksen E., van Bergeijk D., Oosting R.S., Redegeld F.A. Mast cells in neuroinflammation and brain disorders. Neurosci. Biobehav. Rev. 2017;79:119&#x2013;133. doi: 10.1016/j.neubiorev.2017.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2017.05.001</ArticleId><ArticleId IdType="pubmed">28499503</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham C. Microglia and neurodegeneration: The role of systemic inflammation. Glia. 2013;61:71&#x2013;90. doi: 10.1002/glia.22350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22350</ArticleId><ArticleId IdType="pubmed">22674585</ArticleId></ArticleIdList></Reference><Reference><Citation>Skaper S.D., Giusti P., Facci L. Microglia and mast cells: Two tracks on the road to neuroinflammation. FASEB J. 2012;26:3103&#x2013;3117. doi: 10.1096/fj.11-197194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.11-197194</ArticleId><ArticleId IdType="pubmed">22516295</ArticleId></ArticleIdList></Reference><Reference><Citation>Skaper S.D., Facci L., Zusso M., Giusti P. Neuroinflammation, Mast Cells, and Glia: Dangerous Liaisons. Neuroscientist. 2017;23:478&#x2013;498. doi: 10.1177/1073858416687249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073858416687249</ArticleId><ArticleId IdType="pubmed">29283023</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempuraj D., Thangavel R., Selvakumar G.P., Zaheer S., Ahmed M.E., Raikwar S.P., Zahoor H., Saeed D., Natteru P.A., Iyer S., et al. Brain and Peripheral Atypical Inflammatory Mediators Potentiate Neuroinflammation and Neurodegeneration. Front. Cell. Neurosci. 2017;11:216. doi: 10.3389/fncel.2017.00216.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2017.00216</ArticleId><ArticleId IdType="pmc">PMC5522882</ArticleId><ArticleId IdType="pubmed">28790893</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrera-Pastor A., Llansola M., Montoliu C., Malaguarnera M., Balzano T., Taoro-Gonzalez L., Garc&#xed;a-Garc&#xed;a R., Mangas-Losada A., Izquierdo-Altarejos P., Arenas Y.M., et al. Peripheral inflammation induces neuroinflammation that alters neurotransmission and cognitive and motor function in hepatic encephalopathy: Underlying mechanisms and therapeutic implications. Acta Physiol. (Oxf.) 2019;226:e13270. doi: 10.1111/apha.13270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apha.13270</ArticleId><ArticleId IdType="pubmed">30830722</ArticleId></ArticleIdList></Reference><Reference><Citation>Pezzini A., Padovani A. Lifting the mask on neurological manifestations of COVID-19. Nat. Rev. Neurol. 2020;16:636&#x2013;644. doi: 10.1038/s41582-020-0398-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-0398-3</ArticleId><ArticleId IdType="pmc">PMC7444680</ArticleId><ArticleId IdType="pubmed">32839585</ArticleId></ArticleIdList></Reference><Reference><Citation>Farhadian S., Glick L.R., Vogels C.B.F., Thomas J., Chiarella J., Casanovas-Massana A., Zhou J., Odio C., Vijayakumar P., Geng B., et al. Acute encephalopathy with elevated CSF inflammatory markers as the initial presentation of COVID-19. BMC Neurol. 2020;20:248. doi: 10.1186/s12883-020-01812-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-020-01812-2</ArticleId><ArticleId IdType="pmc">PMC7301053</ArticleId><ArticleId IdType="pubmed">32552792</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji R.-R., Chamessian A., Zhang Y.-Q. Pain Regulation by Non-neuronal Cells and Inflammation. Science. 2016;354:572&#x2013;577. doi: 10.1126/science.aaf8924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf8924</ArticleId><ArticleId IdType="pmc">PMC5488328</ArticleId><ArticleId IdType="pubmed">27811267</ArticleId></ArticleIdList></Reference><Reference><Citation>Refolo V., Stefanova N. Neuroinflammation and Glial Phenotypic Changes in Alpha-Synucleinopathies. Front. Cell. Neurosci. 2019;13:263. doi: 10.3389/fncel.2019.00263.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2019.00263</ArticleId><ArticleId IdType="pmc">PMC6585624</ArticleId><ArticleId IdType="pubmed">31263402</ArticleId></ArticleIdList></Reference><Reference><Citation>Skaper S.D., Facci L., Zusso M., Giusti P. An Inflammation-Centric View of Neurological Disease: Beyond the Neuron. Front. Cell. Neurosci. 2018;12:72. doi: 10.3389/fncel.2018.00072.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2018.00072</ArticleId><ArticleId IdType="pmc">PMC5871676</ArticleId><ArticleId IdType="pubmed">29618972</ArticleId></ArticleIdList></Reference><Reference><Citation>Skaper S.D., Facci L. Mast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2012;367:3312&#x2013;3325. doi: 10.1098/rstb.2011.0391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rstb.2011.0391</ArticleId><ArticleId IdType="pmc">PMC3481533</ArticleId><ArticleId IdType="pubmed">23108549</ArticleId></ArticleIdList></Reference><Reference><Citation>Skaper S.D., Facci L., Giusti P. Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator. Mol. Neurobiol. 2013;48:340&#x2013;352. doi: 10.1007/s12035-013-8487-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-013-8487-6</ArticleId><ArticleId IdType="pubmed">23813098</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachur N.R., Masek K., Melmon K.L., Udenfriend S. Fatty acid amides of ethanolamine in mammalian tissues. J. Biol. Chem. 1965;240:1019&#x2013;1024.</Citation><ArticleIdList><ArticleId IdType="pubmed">14284696</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannotti F.A., Di Marzo V., Petrosino S. Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders. Prog. Lipid Res. 2016;62:107&#x2013;128. doi: 10.1016/j.plipres.2016.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.plipres.2016.02.002</ArticleId><ArticleId IdType="pubmed">26965148</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrosino S., Di Marzo V. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br. J. Pharmacol. 2017;174:1349&#x2013;1365. doi: 10.1111/bph.13580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.13580</ArticleId><ArticleId IdType="pmc">PMC5429331</ArticleId><ArticleId IdType="pubmed">27539936</ArticleId></ArticleIdList></Reference><Reference><Citation>Skaper S.D., Facci L., Giusti P. Mast cells, glia and neuroinflammation: Partners in crime? Immunology. 2014;141:314&#x2013;327. doi: 10.1111/imm.12170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.12170</ArticleId><ArticleId IdType="pmc">PMC3930370</ArticleId><ArticleId IdType="pubmed">24032675</ArticleId></ArticleIdList></Reference><Reference><Citation>Piomelli D., Sasso O. Peripheral gating of pain signals by endogenous lipid mediators. Nat. Neurosci. 2014;17:164&#x2013;174. doi: 10.1038/nn.3612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3612</ArticleId><ArticleId IdType="pmc">PMC4020413</ArticleId><ArticleId IdType="pubmed">24473264</ArticleId></ArticleIdList></Reference><Reference><Citation>Skaper S.D., Facci L., Barbierato M., Zusso M., Bruschetta G., Impellizzeri D., Cuzzocrea S., Giusti P. N-Palmitoylethanolamine and Neuroinflammation: A Novel Therapeutic Strategy of Resolution. Mol. Neurobiol. 2015;52:1034&#x2013;1042. doi: 10.1007/s12035-015-9253-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-015-9253-8</ArticleId><ArticleId IdType="pubmed">26055231</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid P.C., Krebsbach R.J., Perry S.R., Dettmer T.M., Maasson J.L., Schmid H.H. Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain. FEBS Lett. 1995;375:117&#x2013;120. doi: 10.1016/0014-5793(95)01194-J.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-5793(95)01194-J</ArticleId><ArticleId IdType="pubmed">7498458</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklin A., Parmentier-Batteur S., Walter L., Greenberg D.A., Stella N. Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J. Neurosci. 2003;23:7767&#x2013;7775. doi: 10.1523/JNEUROSCI.23-21-07767.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.23-21-07767.2003</ArticleId><ArticleId IdType="pmc">PMC6740602</ArticleId><ArticleId IdType="pubmed">12944505</ArticleId></ArticleIdList></Reference><Reference><Citation>Stella N., Piomelli D. Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur. J. Pharmacol. 2001;425:189&#x2013;196. doi: 10.1016/S0014-2999(01)01182-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-2999(01)01182-7</ArticleId><ArticleId IdType="pubmed">11513837</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter L., Franklin A., Witting A., Moller T., Stella N. Astrocytes in culture produce anandamide and other acylethanolamides. J. Biol. Chem. 2002;277:20869&#x2013;20876. doi: 10.1074/jbc.M110813200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110813200</ArticleId><ArticleId IdType="pubmed">11916961</ArticleId></ArticleIdList></Reference><Reference><Citation>Muccioli G.G., Stella N. Microglia produce and hydrolyze palmitoylethanolamide. Neuropharmacology. 2008;54:16&#x2013;22. doi: 10.1016/j.neuropharm.2007.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2007.05.015</ArticleId><ArticleId IdType="pmc">PMC2254322</ArticleId><ArticleId IdType="pubmed">17631917</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker D., Pryce G., Croxford J.L., Brown P., Pertwee R.G., Makriyannis A., Khanolkar A., Layward L., Fezza F., Bisogno T., et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 2001;15:300&#x2013;302. doi: 10.1096/fj.00-0399fje.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.00-0399fje</ArticleId><ArticleId IdType="pubmed">11156943</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrosino S., Palazzo E., de Novellis V., Bisogno T., Rossi F., Maione S., Di Marzo V. Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology. 2007;52:415&#x2013;422. doi: 10.1016/j.neuropharm.2006.08.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2006.08.011</ArticleId><ArticleId IdType="pubmed">17011598</ArticleId></ArticleIdList></Reference><Reference><Citation>Bisogno T., Martire A., Petrosino S., Popoli P., Di Marzo V. Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington&#x2019;s disease. Neurochem. Int. 2008;52:307&#x2013;313. doi: 10.1016/j.neuint.2007.06.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2007.06.031</ArticleId><ArticleId IdType="pubmed">17664017</ArticleId></ArticleIdList></Reference><Reference><Citation>Bisogno T., Delton-Vandenbroucke I., Milone A., Lagarde M., Di Marzo V. Biosynthesis and inactivation of N-arachidonoylethanolamine (anandamide) and N-docosahexaenoylethanolamine in bovine retina. Arch. Biochem. Biophys. 1999;370:300&#x2013;307. doi: 10.1006/abbi.1999.1410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/abbi.1999.1410</ArticleId><ArticleId IdType="pubmed">10577359</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J., Matias I., Dinh T., Lu T., Venezia S., Nieves A., Woodward D.F., Di Marzo V. Finding of endocannabinoids in human eye tissues: Implications for glaucoma. Biochem. Biophys. Res. Commun. 2005;330:1062&#x2013;1067. doi: 10.1016/j.bbrc.2005.03.095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2005.03.095</ArticleId><ArticleId IdType="pubmed">15823551</ArticleId></ArticleIdList></Reference><Reference><Citation>Matias I., Wang J.W., Moriello A.S., Nieves A., Woodward D.F., Di Marzo V. Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration. Prostaglandins Leukot. Essent. Fatty Acids. 2006;75:413&#x2013;418. doi: 10.1016/j.plefa.2006.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.plefa.2006.08.002</ArticleId><ArticleId IdType="pubmed">17011761</ArticleId></ArticleIdList></Reference><Reference><Citation>Epps D.E., Schmid P.C., Natarajan V., Schmid H.H. N-Acylethanolamine accumulation in infarcted myocardium. Biochem. Biophys. Res. Commun. 1979;90:628&#x2013;633. doi: 10.1016/0006-291X(79)91281-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-291X(79)91281-6</ArticleId><ArticleId IdType="pubmed">508325</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo S., Sugiura T., Kodaka T., Kudo N., Waku K., Tokumura A. Accumulation of various N-acylethanolamines including N-arachidonoylethanolamine (anandamide) in cadmium chloride-administered rat testis. Arch. Biochem. Biophys. 1998;354:303&#x2013;310. doi: 10.1006/abbi.1998.0688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/abbi.1998.0688</ArticleId><ArticleId IdType="pubmed">9637740</ArticleId></ArticleIdList></Reference><Reference><Citation>Caraceni P., Viola A., Piscitelli F., Giannone F., Berzigotti A., Cescon M., Domenicali M., Petrosino S., Giampalma E., Riili A., et al. Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis. Liver Int. 2010;30:816&#x2013;825. doi: 10.1111/j.1478-3231.2009.02137.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1478-3231.2009.02137.x</ArticleId><ArticleId IdType="pubmed">19840245</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuel H., Burkman L.J., Lippes J., Crickard K., Forester E., Piomelli D., Giuffrida A. N-Acylethanolamines in human reproductive fluids. Chem. Phys. Lipids. 2002;121:211&#x2013;227. doi: 10.1016/S0009-3084(02)00158-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0009-3084(02)00158-5</ArticleId><ArticleId IdType="pubmed">12505702</ArticleId></ArticleIdList></Reference><Reference><Citation>Capasso R., Izzo A.A., Fezza F., Pinto A., Capasso F., Mascolo N., Di Marzo V. Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. Br. J. Pharmacol. 2001;134:945&#x2013;950. doi: 10.1038/sj.bjp.0704339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjp.0704339</ArticleId><ArticleId IdType="pmc">PMC1573032</ArticleId><ArticleId IdType="pubmed">11682441</ArticleId></ArticleIdList></Reference><Reference><Citation>Darmani N.A., Izzo A.A., Degenhardt B., Valenti M., Scaglione G., Capasso R., Sorrentini I., Di Marzo V. Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: Review of the available pre-clinical data, and first human studies. Neuropharmacology. 2005;48:1154&#x2013;1163. doi: 10.1016/j.neuropharm.2005.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2005.01.001</ArticleId><ArticleId IdType="pubmed">15910891</ArticleId></ArticleIdList></Reference><Reference><Citation>Berdyshev E.V., Schmid P.C., Dong Z., Schmid H.H. Stress-induced generation of N-acylethanolamines in mouse epidermal JB6 P+ cells. Biochem. J. 2000;346:369&#x2013;374. doi: 10.1042/bj3460369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bj3460369</ArticleId><ArticleId IdType="pmc">PMC1220862</ArticleId><ArticleId IdType="pubmed">10677355</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrosino S., Cristino L., Karsak M., Gaffal E., Ueda N., T&#xfc;ting T., Bisogno T., De Filippis D., D&#x2019;Amico A., Saturnino C., et al. Protective role of palmitoylethanolamide in contact allergic dermatitis. Allergy. 2010;65:698&#x2013;711. doi: 10.1111/j.1398-9995.2009.02254.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1398-9995.2009.02254.x</ArticleId><ArticleId IdType="pubmed">19909294</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghafouri N., Ghafouri B., Larsson B., Turkina M.V., Karlsson L., Fowler C.J., Gerdle B. High levels of N-palmitoylethanolamide and N-stearoylethanolamide in microdialysate samples from myalgic trapezius muscle in women. PLoS ONE. 2011;6:e27257. doi: 10.1371/journal.pone.0027257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0027257</ArticleId><ArticleId IdType="pmc">PMC3220690</ArticleId><ArticleId IdType="pubmed">22125609</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghafouri N., Ghafouri B., Larsson B., Stensson N., Fowler C.J., Gerdle B. Palmitoylethanolamide and stearoylethanolamide levels in the interstitium of the trapezius muscle of women with chronic widespread pain and chronic neck-shoulder pain correlate with pain intensity and sensitivity. Pain. 2013;154:1649&#x2013;1658. doi: 10.1016/j.pain.2013.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pain.2013.05.002</ArticleId><ArticleId IdType="pubmed">23707281</ArticleId></ArticleIdList></Reference><Reference><Citation>Giuffrida A., Piomelli D. Isotope dilution GC/MS determination of anandamide and other fatty acylethanolamides in rat blood plasma. FEBS Lett. 1998;422:373&#x2013;376. doi: 10.1016/S0014-5793(98)00046-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-5793(98)00046-5</ArticleId><ArticleId IdType="pubmed">9498819</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber D., Harlfinger S., Nolden B.M., Gerth C.W., Jaehde U., Sch&#xf6;mig E., Klosterk&#xf6;tter J., Giuffrida A., Astarita G., Piomelli D., et al. Determination of anandamide and other fatty acyl ethanolamides in human serum by electrospray tandem mass spectrometry. Anal. Biochem. 2007;361:162&#x2013;168. doi: 10.1016/j.ab.2006.11.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ab.2006.11.027</ArticleId><ArticleId IdType="pubmed">17196922</ArticleId></ArticleIdList></Reference><Reference><Citation>Balvers M.G.J., Verhoeckx K.C.M., Witkamp R.F. Development and validation of a quantitative method for the determination of 12 endocannabinoids and related compounds in human plasma using liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2009;877:1583&#x2013;1590. doi: 10.1016/j.jchromb.2009.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchromb.2009.04.010</ArticleId><ArticleId IdType="pubmed">19395322</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrosino S., Schiano Moriello A., Cerrato S., Fusco M., Puigdemont A., De Petrocellis L., Di Marzo V. The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoyl-glycerol and potentiates its actions at TRPV1 cation channels. Br. J. Pharmacol. 2016;173:1154&#x2013;1162. doi: 10.1111/bph.13084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.13084</ArticleId><ArticleId IdType="pmc">PMC5338153</ArticleId><ArticleId IdType="pubmed">25598150</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam P.M.W., Marczylo T.H., Konje J.C. Simultaneous measurement of three N-acylethanolamides in human bio-matrices using ultra performance liquid chromatography-tandem mass spectrometry. Anal. Bioanal. Chem. 2010;398:2089&#x2013;2097. doi: 10.1007/s00216-010-4103-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00216-010-4103-z</ArticleId><ArticleId IdType="pubmed">20835819</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrera M.I., Udovin L.D., Toro-Urrego N., Kusnier C.F., Luaces J.P., Capani F. Palmitoylethanolamide Ameliorates Hippocampal Damage and Behavioral Dysfunction After Perinatal Asphyxia in the Immature Rat Brain. Front. Neurosci. 2018;12:145. doi: 10.3389/fnins.2018.00145.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2018.00145</ArticleId><ArticleId IdType="pmc">PMC5890174</ArticleId><ArticleId IdType="pubmed">29662433</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagberg H., Mallard C., Ferriero D.M., Vannucci S.J., Levison S.W., Vexler Z.S., Gressens P. The role of inflammation in perinatal brain injury. Nat. Rev. Neurol. 2015;11:192&#x2013;208. doi: 10.1038/nrneurol.2015.13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2015.13</ArticleId><ArticleId IdType="pmc">PMC4664161</ArticleId><ArticleId IdType="pubmed">25686754</ArticleId></ArticleIdList></Reference><Reference><Citation>Coburn A.F., Graham C.E., Haninger J. The effect of egg yolk in diets on anaphylactic arthritis (passive Arthus phenomenon) in the guinea pig. J. Exp. Med. 1954;100:425&#x2013;435. doi: 10.1084/jem.100.5.425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.100.5.425</ArticleId><ArticleId IdType="pmc">PMC2136389</ArticleId><ArticleId IdType="pubmed">13211905</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuehl F.A., Jacob T.A., Ganley O.H., Ormond R.E., Meisinger M.A.P. The identification of N-(2-hydroxyethyl)-palmitamide as a naturally occurring anti-inflammatory agent. J. Am. Chem. Soc. 1957;79:5577&#x2013;5578. doi: 10.1021/ja01577a066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja01577a066</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilaru A., Blancaflor E.B., Venables B.J., Tripathy S., Mysore K.S., Chapman K.D. The N-acylethanolamine-mediated regulatory pathway in plants. Chem. Biodivers. 2007;4:1933&#x2013;1955. doi: 10.1002/cbdv.200790161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbdv.200790161</ArticleId><ArticleId IdType="pubmed">17712835</ArticleId></ArticleIdList></Reference><Reference><Citation>Venables B.J., Waggoner C.A., Chapman K.D. N-acylethanolamines in seeds of selected legumes. Phytochemistry. 2005;66:1913&#x2013;1918. doi: 10.1016/j.phytochem.2005.06.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phytochem.2005.06.014</ArticleId><ArticleId IdType="pubmed">16054175</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouveia-Figueira S., Nording M.L. Development and validation of a sensitive UPLC-ESI-MS/MS method for the simultaneous quantification of 15 endocannabinoids and related compounds in milk and other biofluids. Anal. Chem. 2014;86:1186&#x2013;1195. doi: 10.1021/ac403352e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ac403352e</ArticleId><ArticleId IdType="pubmed">24377270</ArticleId></ArticleIdList></Reference><Reference><Citation>Impellizzeri D., Cordaro M., Bruschetta G., Crupi R., Pascali J., Alfonsi D., Marcolongo G., Cuzzocrea S. 2-pentadecyl-2-oxazoline: Identification in coffee, synthesis and activity in a rat model of carrageenan-induced hindpaw inflammation. Pharmacol. Res. 2016;108:23&#x2013;30. doi: 10.1016/j.phrs.2016.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2016.04.007</ArticleId><ArticleId IdType="pubmed">27083308</ArticleId></ArticleIdList></Reference><Reference><Citation>Skaper S.D., Di Marzo V. Endocannabinoids in nervous system health and disease: The big picture in a nutshell. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2012;367:3193&#x2013;3200. doi: 10.1098/rstb.2012.0313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rstb.2012.0313</ArticleId><ArticleId IdType="pmc">PMC3481537</ArticleId><ArticleId IdType="pubmed">23108539</ArticleId></ArticleIdList></Reference><Reference><Citation>Guasti L., Richardson D., Jhaveri M., Eldeeb K., Barrett D., Elphick M.R., Alexander S.P.H., Kendall D., Michael G.J., Chapman V. Minocycline treatment inhibits microglial activation and alters spinal levels of endocannabinoids in a rat model of neuropathic pain. Mol. Pain. 2009;5:35. doi: 10.1186/1744-8069-5-35.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1744-8069-5-35</ArticleId><ArticleId IdType="pmc">PMC2719614</ArticleId><ArticleId IdType="pubmed">19570201</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry R.J., Kerr D.M., Flannery L.E., Killilea M., Hughes E.M., Corcoran L., Finn D.P., Roche M. Pharmacological inhibition of FAAH modulates TLR-induced neuroinflammation, but not sickness behaviour: An effect partially mediated by central TRPV1. Brain Behav. Immun. 2017;62:318&#x2013;331. doi: 10.1016/j.bbi.2017.02.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2017.02.016</ArticleId><ArticleId IdType="pubmed">28237711</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L., Ji C., Li Y., Hu F., Zhang F., Zhang H., Li L., Ren J., Wang Z., Qiu Y. Natural Potent NAAA Inhibitor Atractylodin Counteracts LPS-Induced Microglial Activation. Front. Pharmacol. 2020;11:1546. doi: 10.3389/fphar.2020.577319.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.577319</ArticleId><ArticleId IdType="pmc">PMC7565389</ArticleId><ArticleId IdType="pubmed">33117168</ArticleId></ArticleIdList></Reference><Reference><Citation>Skaper S.D., Facci L., Fusco M., Della Valle M.F., Zusso M., Costa B., Giusti P. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology. 2014;22:79&#x2013;94. doi: 10.1007/s10787-013-0191-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-013-0191-7</ArticleId><ArticleId IdType="pubmed">24178954</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordaro M., Cuzzocrea S., Crupi R. An Update of Palmitoylethanolamide and Luteolin Effects in Preclinical and Clinical Studies of Neuroinflammatory Events. Antioxidants (Basel) 2020;9:216. doi: 10.3390/antiox9030216.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox9030216</ArticleId><ArticleId IdType="pmc">PMC7139331</ArticleId><ArticleId IdType="pubmed">32150935</ArticleId></ArticleIdList></Reference><Reference><Citation>De Luca L., Ferracane R., Vitaglione P. Food database of N-acyl-phosphatidylethanolamines, N-acylethanolamines and endocannabinoids and daily intake from a Western, a Mediterranean and a vegetarian diet. Food Chem. 2019;300:125218. doi: 10.1016/j.foodchem.2019.125218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.foodchem.2019.125218</ArticleId><ArticleId IdType="pubmed">31351254</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepe N., De Petrocellis L., Montanaro F., Cimino G., Di Marzo V. Bioactive long chain N-acylethanolamines in five species of edible bivalve molluscs. Possible implications for mollusc physiology and sea food industry. Biochim. Biophys. Acta. 1998;1389:101&#x2013;111. doi: 10.1016/S0005-2760(97)00132-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0005-2760(97)00132-X</ArticleId><ArticleId IdType="pubmed">9461251</ArticleId></ArticleIdList></Reference><Reference><Citation>Impellizzeri D., Bruschetta G., Cordaro M., Crupi R., Siracusa R., Esposito E., Cuzzocrea S. Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. J. Neuroinflamm. 2014;11:136. doi: 10.1186/s12974-014-0136-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-014-0136-0</ArticleId><ArticleId IdType="pmc">PMC4171547</ArticleId><ArticleId IdType="pubmed">25164769</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrosino S., Cordaro M., Verde R., Schiano Moriello A., Marcolongo G., Schievano C., Siracusa R., Piscitelli F., Peritore A.F., Crupi R., et al. Oral Ultramicronized Palmitoylethanolamide: Plasma and Tissue Levels and Spinal Anti-hyperalgesic Effect. Front. Pharmacol. 2018;9:249. doi: 10.3389/fphar.2018.00249.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2018.00249</ArticleId><ArticleId IdType="pmc">PMC5870042</ArticleId><ArticleId IdType="pubmed">29615912</ArticleId></ArticleIdList></Reference><Reference><Citation>Beggiato S., Tomasini M.C., Cassano T., Ferraro L. Chronic Oral Palmitoylethanolamide Administration Rescues Cognitive Deficit and Reduces Neuroinflammation, Oxidative Stress, and Glutamate Levels in A Transgenic Murine Model of Alzheimer&#x2019;s Disease. J. Clin. Med. 2020;9:428. doi: 10.3390/jcm9020428.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9020428</ArticleId><ArticleId IdType="pmc">PMC7074257</ArticleId><ArticleId IdType="pubmed">32033363</ArticleId></ArticleIdList></Reference><Reference><Citation>Nestmann E.R. Safety of micronized palmitoylethanolamide (microPEA): Lack of toxicity and genotoxic potential. Food Sci. Nutr. 2017;5:292&#x2013;309. doi: 10.1002/fsn3.392.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/fsn3.392</ArticleId><ArticleId IdType="pmc">PMC5332261</ArticleId><ArticleId IdType="pubmed">28265364</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor J.M., Main B.S., Crack P.J. Neuroinflammation and oxidative stress: Co-conspirators in the pathology of Parkinson&#x2019;s disease. Neurochem. Int. 2013;62:803&#x2013;819. doi: 10.1016/j.neuint.2012.12.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2012.12.016</ArticleId><ArticleId IdType="pubmed">23291248</ArticleId></ArticleIdList></Reference><Reference><Citation>Crupi R., Impellizzeri D., Cordaro M., Siracusa R., Casili G., Evangelista M., Cuzzocrea S. N-palmitoylethanolamide Prevents Parkinsonian Phenotypes in Aged Mice. Mol. Neurobiol. 2018;55:8455&#x2013;8472. doi: 10.1007/s12035-018-0959-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-0959-2</ArticleId><ArticleId IdType="pubmed">29552727</ArticleId></ArticleIdList></Reference><Reference><Citation>Vafeiadou K., Vauzour D., Spencer J.P.E. Neuroinflammation and its modulation by flavonoids. Endocr. Metab. Immune Disord. Drug Targets. 2007;7:211&#x2013;224. doi: 10.2174/187153007781662521.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/187153007781662521</ArticleId><ArticleId IdType="pubmed">17897048</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabavi S.F., Braidy N., Gortzi O., Sobarzo-Sanchez E., Daglia M., Skalicka-Wo&#x17a;niak K., Nabavi S.M. Luteolin as an anti-inflammatory and neuroprotective agent: A brief review. Brain Res. Bull. 2015;119:1&#x2013;11. doi: 10.1016/j.brainresbull.2015.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2015.09.002</ArticleId><ArticleId IdType="pubmed">26361743</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Q.-H., Peng C., Zhang H. Polydatin: A review of pharmacology and pharmacokinetics. Pharm. Biol. 2013;51:1347&#x2013;1354. doi: 10.3109/13880209.2013.792849.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/13880209.2013.792849</ArticleId><ArticleId IdType="pubmed">23862567</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito E., Impellizzeri D., Mazzon E., Paterniti I., Cuzzocrea S. Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinson&#x2019;s disease. PLoS ONE. 2012;7:e41880. doi: 10.1371/journal.pone.0041880.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0041880</ArticleId><ArticleId IdType="pmc">PMC3422290</ArticleId><ArticleId IdType="pubmed">22912680</ArticleId></ArticleIdList></Reference><Reference><Citation>Siracusa R., Paterniti I., Impellizzeri D., Cordaro M., Crupi R., Navarra M., Cuzzocrea S., Esposito E. The Association of Palmitoylethanolamide with Luteolin Decreases Neuroinflammation and Stimulates Autophagy in Parkinson&#x2019;s Disease Model. CNS Neurol. Disord. Drug Targets. 2015;14:1350&#x2013;1365. doi: 10.2174/1871527314666150821102823.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871527314666150821102823</ArticleId><ArticleId IdType="pubmed">26295827</ArticleId></ArticleIdList></Reference><Reference><Citation>Avagliano C., Russo R., De Caro C., Cristiano C., La Rana G., Piegari G., Paciello O., Citraro R., Russo E., De Sarro G., et al. Palmitoylethanolamide protects mice against 6-OHDA-induced neurotoxicity and endoplasmic reticulum stress: In vivo and in vitro evidence. Pharmacol. Res. 2016;113:276&#x2013;289. doi: 10.1016/j.phrs.2016.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2016.09.004</ArticleId><ArticleId IdType="pubmed">27616549</ArticleId></ArticleIdList></Reference><Reference><Citation>Brotini S., Schievano C., Guidi L. Ultra-micronized Palmitoylethanolamide: An Efficacious Adjuvant Therapy for Parkinson&#x2019;s Disease. CNS Neurol. Disord. Drug Targets. 2017;16:705&#x2013;713. doi: 10.2174/1871527316666170321124949.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871527316666170321124949</ArticleId><ArticleId IdType="pubmed">28325153</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Agostino G., Russo R., Avagliano C., Cristiano C., Meli R., Calignano A. Palmitoylethanolamide protects against the amyloid-&#x3b2;25-35-induced learning and memory impairment in mice, an experimental model of Alzheimer disease. Neuropsychopharmacology. 2012;37:1784&#x2013;1792. doi: 10.1038/npp.2012.25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npp.2012.25</ArticleId><ArticleId IdType="pmc">PMC3358748</ArticleId><ArticleId IdType="pubmed">22414817</ArticleId></ArticleIdList></Reference><Reference><Citation>Scuderi C., Stecca C., Valenza M., Ratano P., Bronzuoli M.R., Bartoli S., Steardo L., Pompili E., Fumagalli L., Campolongo P., et al. Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer&#x2019;s disease. Cell Death Dis. 2014;5:e1419. doi: 10.1038/cddis.2014.376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2014.376</ArticleId><ArticleId IdType="pmc">PMC4540191</ArticleId><ArticleId IdType="pubmed">25210802</ArticleId></ArticleIdList></Reference><Reference><Citation>Scuderi C., Bronzuoli M.R., Facchinetti R., Pace L., Ferraro L., Broad K.D., Serviddio G., Bellanti F., Palombelli G., Carpinelli G., et al. Ultramicronized palmitoylethanolamide rescues learning and memory impairments in a triple transgenic mouse model of Alzheimer&#x2019;s disease by exerting anti-inflammatory and neuroprotective effects. Transl. Psychiatry. 2018;8:32. doi: 10.1038/s41398-017-0076-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-017-0076-4</ArticleId><ArticleId IdType="pmc">PMC5802581</ArticleId><ArticleId IdType="pubmed">29382825</ArticleId></ArticleIdList></Reference><Reference><Citation>Bronzuoli M.R., Facchinetti R., Steardo L., Romano A., Stecca C., Passarella S., Steardo L., Cassano T., Scuderi C. Palmitoylethanolamide Dampens Reactive Astrogliosis and Improves Neuronal Trophic Support in a Triple Transgenic Model of Alzheimer&#x2019;s Disease: In Vitro and In Vivo Evidence. Oxid. Med. Cell. Longev. 2018;2018:4720532. doi: 10.1155/2018/4720532.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/4720532</ArticleId><ArticleId IdType="pmc">PMC5822864</ArticleId><ArticleId IdType="pubmed">29576849</ArticleId></ArticleIdList></Reference><Reference><Citation>Facchinetti R., Valenza M., Bronzuoli M.R., Menegoni G., Ratano P., Steardo L., Campolongo P., Scuderi C. Looking for a Treatment for the Early Stage of Alzheimer&#x2019;s Disease: Preclinical Evidence with Co-Ultramicronized Palmitoylethanolamide and Luteolin. Int. J. Mol. Sci. 2020;21:3802. doi: 10.3390/ijms21113802.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21113802</ArticleId><ArticleId IdType="pmc">PMC7312730</ArticleId><ArticleId IdType="pubmed">32471239</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabr&#xf2; R.S., Naro A., De Luca R., Leonardi S., Russo M., Marra A., Bramanti P. PEALut efficacy in mild cognitive impairment: Evidence from a SPECT case study! Aging Clin. Exp. Res. 2016;28:1279&#x2013;1282. doi: 10.1007/s40520-016-0533-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40520-016-0533-6</ArticleId><ArticleId IdType="pubmed">26820462</ArticleId></ArticleIdList></Reference><Reference><Citation>Lor&#xed;a F., Petrosino S., Mestre L., Spagnolo A., Correa F., Hernang&#xf3;mez M., Guaza C., Di Marzo V., Docagne F. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur. J. Neurosci. 2008;28:633&#x2013;641. doi: 10.1111/j.1460-9568.2008.06377.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2008.06377.x</ArticleId><ArticleId IdType="pubmed">18657182</ArticleId></ArticleIdList></Reference><Reference><Citation>Contarini G., Franceschini D., Facci L., Barbierato M., Giusti P., Zusso M. A Co-Ultramicronized Palmitoylethanolamide/Luteolin Composite Mitigates Clinical Score and Disease-Relevant Molecular Markers in a Mouse Model of Experimental Autoimmune Encephalomyelitis. J. Neuroinflamm. 2019;16:126. doi: 10.1186/s12974-019-1514-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1514-4</ArticleId><ArticleId IdType="pmc">PMC6587257</ArticleId><ArticleId IdType="pubmed">31221190</ArticleId></ArticleIdList></Reference><Reference><Citation>Orefice N.S., Alhouayek M., Carotenuto A., Montella S., Barbato F., Comelli A., Calignano A., Muccioli G.G., Orefice G. Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-&#x3b2;1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis. Neurotherapeutics. 2016;13:428&#x2013;438. doi: 10.1007/s13311-016-0420-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0420-z</ArticleId><ArticleId IdType="pmc">PMC4824021</ArticleId><ArticleId IdType="pubmed">26857391</ArticleId></ArticleIdList></Reference><Reference><Citation>Clemente S. Amyotrophic lateral sclerosis treatment with ultramicronized palmitoylethanolamide: A case report. CNS Neurol. Disord. Drug Targets. 2012;11:933&#x2013;936. doi: 10.2174/1871527311201070933.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871527311201070933</ArticleId><ArticleId IdType="pubmed">22998138</ArticleId></ArticleIdList></Reference><Reference><Citation>Palma E., Reyes-Ruiz J.M., Lopergolo D., Roseti C., Bertollini C., Ruffolo G., Cifelli P., Onesti E., Limatola C., Miledi R., et al. Acetylcholine receptors from human muscle as pharmacological targets for ALS therapy. Proc. Natl. Acad. Sci. USA. 2016;113:3060&#x2013;3065. doi: 10.1073/pnas.1600251113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1600251113</ArticleId><ArticleId IdType="pmc">PMC4801305</ArticleId><ArticleId IdType="pubmed">26929355</ArticleId></ArticleIdList></Reference><Reference><Citation>Onesti E., Frasca V., Ceccanti M., Tartaglia G., Gori M.C., Cambieri C., Libonati L., Palma E., Inghilleri M. Short-Term Ultramicronized Palmitoylethanolamide Therapy in Patients with Myasthenia Gravis: A Pilot Study to Possible Future Implications of Treatment. CNS Neurol. Disord. Drug Targets. 2019;18:232&#x2013;238. doi: 10.2174/1871527318666190131121827.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871527318666190131121827</ArticleId><ArticleId IdType="pubmed">30706796</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertolino B., Crupi R., Impellizzeri D., Bruschetta G., Cordaro M., Siracusa R., Esposito E., Cuzzocrea S. Beneficial Effects of Co-Ultramicronized Palmitoylethanolamide/Luteolin in a Mouse Model of Autism and in a Case Report of Autism. CNS Neurosci. Ther. 2017;23:87&#x2013;98. doi: 10.1111/cns.12648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.12648</ArticleId><ArticleId IdType="pmc">PMC6492645</ArticleId><ArticleId IdType="pubmed">27701827</ArticleId></ArticleIdList></Reference><Reference><Citation>Cristiano C., Pirozzi C., Coretti L., Cavaliere G., Lama A., Russo R., Lembo F., Mollica M.P., Meli R., Calignano A., et al. Palmitoylethanolamide counteracts autistic-like behaviours in BTBR T+tf/J mice: Contribution of central and peripheral mechanisms. Brain Behav. Immun. 2018;74:166&#x2013;175. doi: 10.1016/j.bbi.2018.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2018.09.003</ArticleId><ArticleId IdType="pubmed">30193877</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonucci N., Cirillo A., Siniscalco D. Beneficial Effects of Palmitoylethanolamide on Expressive Language, Cognition, and Behaviors in Autism: A Report of Two Cases. Case Rep. Psychiatry. 2015;2015:325061. doi: 10.1155/2015/325061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/325061</ArticleId><ArticleId IdType="pmc">PMC4602323</ArticleId><ArticleId IdType="pubmed">26491593</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa B., Comelli F., Bettoni I., Colleoni M., Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: Involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain. 2008;139:541&#x2013;550. doi: 10.1016/j.pain.2008.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pain.2008.06.003</ArticleId><ArticleId IdType="pubmed">18602217</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettoni I., Comelli F., Colombo A., Bonfanti P., Costa B. Non-neuronal cell modulation relieves neuropathic pain: Efficacy of the endogenous lipid palmitoylethanolamide. CNS Neurol. Disord. Drug Targets. 2013;12:34&#x2013;44. doi: 10.2174/1871527311312010008.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871527311312010008</ArticleId><ArticleId IdType="pubmed">23394519</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Cesare Mannelli L., D&#x2019;Agostino G., Pacini A., Russo R., Zanardelli M., Ghelardini C., Calignano A. Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: Pain relief and neuroprotection share a PPAR-alpha-mediated mechanism. Mediat. Inflamm. 2013;2013:328797. doi: 10.1155/2013/328797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/328797</ArticleId><ArticleId IdType="pmc">PMC3596927</ArticleId><ArticleId IdType="pubmed">23533304</ArticleId></ArticleIdList></Reference><Reference><Citation>Luongo L., Guida F., Boccella S., Bellini G., Gatta L., Rossi F., de Novellis V., Maione S. Palmitoylethanolamide reduces formalin-induced neuropathic-like behaviour through spinal glial/microglial phenotypical changes in mice. CNS Neurol. Disord. Drug Targets. 2013;12:45&#x2013;54. doi: 10.2174/1871527311312010009.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871527311312010009</ArticleId><ArticleId IdType="pubmed">23394524</ArticleId></ArticleIdList></Reference><Reference><Citation>Guida F., Luongo L., Marmo F., Romano R., Iannotta M., Napolitano F., Belardo C., Marabese I., D&#x2019;Aniello A., De Gregorio D., et al. Palmitoylethanolamide reduces pain-related behaviors and restores glutamatergic synapses homeostasis in the medial prefrontal cortex of neuropathic mice. Mol. Brain. 2015;8:47. doi: 10.1186/s13041-015-0139-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-015-0139-5</ArticleId><ArticleId IdType="pmc">PMC4532244</ArticleId><ArticleId IdType="pubmed">26260027</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Cesare Mannelli L., Pacini A., Corti F., Boccella S., Luongo L., Esposito E., Cuzzocrea S., Maione S., Calignano A., Ghelardini C. Antineuropathic profile of N-palmitoylethanolamine in a rat model of oxaliplatin-induced neurotoxicity. PLoS ONE. 2015;10:e0128080. doi: 10.1371/journal.pone.0128080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0128080</ArticleId><ArticleId IdType="pmc">PMC4454493</ArticleId><ArticleId IdType="pubmed">26039098</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasso O., Russo R., Vitiello S., Raso G.M., D&#x2019;Agostino G., Iacono A., Rana G.L., Vall&#xe9;e M., Cuzzocrea S., Piazza P.V., et al. Implication of allopregnanolone in the antinociceptive effect of N-palmitoylethanolamide in acute or persistent pain. Pain. 2012;153:33&#x2013;41. doi: 10.1016/j.pain.2011.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pain.2011.08.010</ArticleId><ArticleId IdType="pubmed">21890273</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Cesare Mannelli L., Corti F., Micheli L., Zanardelli M., Ghelardini C. Delay of morphine tolerance by palmitoylethanolamide. Biomed. Res. Int. 2015;2015:894732. doi: 10.1155/2015/894732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/894732</ArticleId><ArticleId IdType="pmc">PMC4385605</ArticleId><ArticleId IdType="pubmed">25874232</ArticleId></ArticleIdList></Reference><Reference><Citation>Boccella S., Cristiano C., Romano R., Iannotta M., Belardo C., Farina A., Guida F., Piscitelli F., Palazzo E., Mazzitelli M., et al. Ultra-micronized palmitoylethanolamide rescues the cognitive decline-associated loss of neural plasticity in the neuropathic mouse entorhinal cortex-dentate gyrus pathway. Neurobiol. Dis. 2019;121:106&#x2013;119. doi: 10.1016/j.nbd.2018.09.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2018.09.023</ArticleId><ArticleId IdType="pubmed">30266286</ArticleId></ArticleIdList></Reference><Reference><Citation>Fusco R., Gugliandolo E., Campolo M., Evangelista M., Di Paola R., Cuzzocrea S. Effect of a new formulation of micronized and ultramicronized N-palmitoylethanolamine in a tibia fracture mouse model of complex regional pain syndrome. PLoS ONE. 2017;12:e0178553. doi: 10.1371/journal.pone.0178553.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0178553</ArticleId><ArticleId IdType="pmc">PMC5464592</ArticleId><ArticleId IdType="pubmed">28594885</ArticleId></ArticleIdList></Reference><Reference><Citation>Peritore A.F., Siracusa R., Fusco R., Gugliandolo E., D&#x2019;Amico R., Cordaro M., Crupi R., Genovese T., Impellizzeri D., Cuzzocrea S., et al. Ultramicronized Palmitoylethanolamide and Paracetamol, a New Association to Relieve Hyperalgesia and Pain in a Sciatic Nerve Injury Model in Rat. Int. J. Mol. Sci. 2020;21:3509. doi: 10.3390/ijms21103509.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21103509</ArticleId><ArticleId IdType="pmc">PMC7278943</ArticleId><ArticleId IdType="pubmed">32429243</ArticleId></ArticleIdList></Reference><Reference><Citation>Siracusa R., Fusco R., Cordaro M., Peritore A.F., D&#x2019;Amico R., Gugliandolo E., Crupi R., Genovese T., Evangelista M., Di Paola R., et al. The Protective Effects of Pre- and Post-Administration of Micronized Palmitoylethanolamide Formulation on Postoperative Pain in Rats. Int. J. Mol. Sci. 2020;21:7700. doi: 10.3390/ijms21207700.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21207700</ArticleId><ArticleId IdType="pmc">PMC7589788</ArticleId><ArticleId IdType="pubmed">33080989</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatti A., Lazzari M., Gianfelice V., Di Paolo A., Sabato E., Sabato A.F. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med. 2012;13:1121&#x2013;1130. doi: 10.1111/j.1526-4637.2012.01432.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1526-4637.2012.01432.x</ArticleId><ArticleId IdType="pubmed">22845893</ArticleId></ArticleIdList></Reference><Reference><Citation>Cocito D., Peci E., Ciaramitaro P., Merola A., Lopiano L. Short-term efficacy of ultramicronized palmitoylethanolamide in peripheral neuropathic pain. Pain Res. Treat. 2014;2014:854560. doi: 10.1155/2014/854560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/854560</ArticleId><ArticleId IdType="pmc">PMC4055055</ArticleId><ArticleId IdType="pubmed">24967102</ArticleId></ArticleIdList></Reference><Reference><Citation>Chirchiglia D., Paventi S., Seminara P., Cione E., Gallelli L. N-Palmitoyl Ethanol Amide Pharmacological Treatment in Patients with Nonsurgical Lumbar Radiculopathy. J. Clin. Pharmacol. 2018;58:733&#x2013;739. doi: 10.1002/jcph.1070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcph.1070</ArticleId><ArticleId IdType="pubmed">29364513</ArticleId></ArticleIdList></Reference><Reference><Citation>Passavanti M.B., Fiore M., Sansone P., Aurilio C., Pota V., Barbarisi M., Fierro D., Pace M.C. The beneficial use of ultramicronized palmitoylethanolamide as add-on therapy to Tapentadol in the treatment of low back pain: A pilot study comparing prospective and retrospective observational arms. BMC Anesthesiol. 2017;17:171. doi: 10.1186/s12871-017-0461-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12871-017-0461-9</ArticleId><ArticleId IdType="pmc">PMC5735888</ArticleId><ArticleId IdType="pubmed">29258432</ArticleId></ArticleIdList></Reference><Reference><Citation>Paladini A., Varrassi G., Bentivegna G., Carletti S., Piroli A., Coaccioli S. Palmitoylethanolamide in the Treatment of Failed Back Surgery Syndrome. Pain Res. Treat. 2017;2017:1486010. doi: 10.1155/2017/1486010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/1486010</ArticleId><ArticleId IdType="pmc">PMC5569747</ArticleId><ArticleId IdType="pubmed">28875041</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaturro D., Asaro C., Lauricella L., Tomasello S., Varrassi G., Letizia Mauro G. Combination of Rehabilitative Therapy with Ultramicronized Palmitoylethanolamide for Chronic Low Back Pain: An Observational Study. Pain Ther. 2020;9:319&#x2013;326. doi: 10.1007/s40122-019-00140-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40122-019-00140-9</ArticleId><ArticleId IdType="pmc">PMC7203351</ArticleId><ArticleId IdType="pubmed">31863365</ArticleId></ArticleIdList></Reference><Reference><Citation>Evangelista M., Cilli V., De Vitis R., Militerno A., Fanfani F. Ultra-micronized Palmitoylethanolamide Effects on Sleep-wake Rhythm and Neuropathic Pain Phenotypes in Patients with Carpal Tunnel Syndrome: An Open-label, Randomized Controlled Study. CNS Neurol. Disord. Drug Targets. 2018;17:291&#x2013;298. doi: 10.2174/1871527317666180420143830.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871527317666180420143830</ArticleId><ArticleId IdType="pubmed">29676237</ArticleId></ArticleIdList></Reference><Reference><Citation>Iuvone T., Affaitati G., De Filippis D., Lopopolo M., Grassia G., Lapenna D., Negro L., Costantini R., Vaia M., Cipollone F., et al. Ultramicronized palmitoylethanolamide reduces viscerovisceral hyperalgesia in a rat model of endometriosis plus ureteral calculosis: Role of mast cells. Pain. 2016;157:80&#x2013;91. doi: 10.1097/j.pain.0000000000000220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/j.pain.0000000000000220</ArticleId><ArticleId IdType="pubmed">25974242</ArticleId></ArticleIdList></Reference><Reference><Citation>Indraccolo U., Barbieri F. Effect of palmitoylethanolamide-polydatin combination on chronic pelvic pain associated with endometriosis: Preliminary observations. Eur. J. Obstet. Gynecol. Reprod. Biol. 2010;150:76&#x2013;79. doi: 10.1016/j.ejogrb.2010.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejogrb.2010.01.008</ArticleId><ArticleId IdType="pubmed">20176435</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo Monte G., Soave I., Marci R. Administration of micronized palmitoylethanolamide (PEA)-transpolydatin in the treatment of chronic pelvic pain in women affected by endometriosis: Preliminary results. Minerva Ginecol. 2013;65:453&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">24051945</ArticleId></ArticleIdList></Reference><Reference><Citation>Cobellis L., Castaldi M.A., Giordano V., Trabucco E., De Franciscis P., Torella M., Colacurci N. Effectiveness of the association micronized N-Palmitoylethanolamine (PEA)-transpolydatin in the treatment of chronic pelvic pain related to endometriosis after laparoscopic assessment: A pilot study. Eur. J. Obstet. Gynecol. Reprod. Biol. 2011;158:82&#x2013;86. doi: 10.1016/j.ejogrb.2011.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejogrb.2011.04.011</ArticleId><ArticleId IdType="pubmed">21601979</ArticleId></ArticleIdList></Reference><Reference><Citation>Giugliano E., Cagnazzo E., Soave I., Lo Monte G., Wenger J.M., Marci R. The adjuvant use of N-palmitoylethanolamine and transpolydatin in the treatment of endometriotic pain. Eur. J. Obstet. Gynecol. Reprod. Biol. 2013;168:209&#x2013;213. doi: 10.1016/j.ejogrb.2013.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejogrb.2013.01.009</ArticleId><ArticleId IdType="pubmed">23415738</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartaglia E., Armentano M., Giugliano B., Sena T., Giuliano P., Loffredo C., Mastrantonio P. Effectiveness of the Association N-Palmitoylethanolamine and Transpolydatin in the Treatment of Primary Dysmenorrhea. J. Pediatric Adolesc. Gynecol. 2015;28:447&#x2013;450. doi: 10.1016/j.jpag.2014.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpag.2014.12.011</ArticleId><ArticleId IdType="pubmed">26233289</ArticleId></ArticleIdList></Reference><Reference><Citation>Stochino Loi E., Pontis A., Cofelice V., Pirarba S., Fais M.F., Daniilidis A., Melis I., Paoletti A.M., Angioni S. Effect of ultramicronized-palmitoylethanolamide and co-micronized palmitoylethanolamide/polydatin on chronic pelvic pain and quality of life in endometriosis patients: An open-label pilot study. Int. J. Women&#x2019;s Health. 2019;11:443&#x2013;449. doi: 10.2147/IJWH.S204275.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJWH.S204275</ArticleId><ArticleId IdType="pmc">PMC6697671</ArticleId><ArticleId IdType="pubmed">31496832</ArticleId></ArticleIdList></Reference><Reference><Citation>Chirchiglia D., Della Torre A., Signorelli F., Volpentesta G., Guzzi G., Stroscio C.A., Deodato F., Gabriele D., Lavano A. Administration of palmitoylethanolamide in combination with topiramate in the preventive treatment of nummular headache. Int. Med. Case Rep. J. 2016;9:193&#x2013;195. doi: 10.2147/IMCRJ.S106323.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IMCRJ.S106323</ArticleId><ArticleId IdType="pmc">PMC4957685</ArticleId><ArticleId IdType="pubmed">27486344</ArticleId></ArticleIdList></Reference><Reference><Citation>Chirchiglia D., Cione E., Caroleo M.C., Wang M., Di Mizio G., Faedda N., Giacolini T., Siviglia S., Guidetti V., Gallelli L. Effects of Add-On Ultramicronized N-Palmitol Ethanol Amide in Patients Suffering of Migraine with Aura: A Pilot Study. Front. Neurol. 2018;9:674. doi: 10.3389/fneur.2018.00674.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.00674</ArticleId><ArticleId IdType="pmc">PMC6109682</ArticleId><ArticleId IdType="pubmed">30177906</ArticleId></ArticleIdList></Reference><Reference><Citation>Papetti L., Sforza G., Tullo G., Alaimo di Loro P., Moavero R., Ursitti F., Ferilli M.A.N., Tarantino S., Vigevano F., Valeriani M. Tolerability of Palmitoylethanolamide in a Pediatric Population Suffering from Migraine: A Pilot Study. Pain Res. Manag. 2020;2020:3938640. doi: 10.1155/2020/3938640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/3938640</ArticleId><ArticleId IdType="pmc">PMC7196162</ArticleId><ArticleId IdType="pubmed">32377286</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Giorno R., Skaper S., Paladini A., Varrassi G., Coaccioli S. Palmitoylethanolamide in Fibromyalgia: Results from Prospective and Retrospective Observational Studies. Pain Ther. 2015;4:169&#x2013;178. doi: 10.1007/s40122-015-0038-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40122-015-0038-6</ArticleId><ArticleId IdType="pmc">PMC4676767</ArticleId><ArticleId IdType="pubmed">26334329</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweiger V., Martini A., Bellamoli P., Donadello K., Schievano C., Del Balzo G., Sarzi-Puttini P., Parolini M., Polati E. Ultramicronized Palmitoylethanolamide (um-PEA) as add-on Treatment in Fibromyalgia Syndrome (FMS): Retrospective Observational Study on 407 Patients. CNS Neurol. Disord. Drug Targets. 2019;18:326&#x2013;333. doi: 10.2174/1871527318666190227205359.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871527318666190227205359</ArticleId><ArticleId IdType="pubmed">30827269</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto Y., Morishita J., Tsuboi K., Tonai T., Ueda N. Molecular characterization of a phospholipase D generating anandamide and its congeners. J. Biol. Chem. 2004;279:5298&#x2013;5305. doi: 10.1074/jbc.M306642200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M306642200</ArticleId><ArticleId IdType="pubmed">14634025</ArticleId></ArticleIdList></Reference><Reference><Citation>Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 1996;384:83&#x2013;87. doi: 10.1038/384083a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/384083a0</ArticleId><ArticleId IdType="pubmed">8900284</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueda N., Yamanaka K., Yamamoto S. Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. J. Biol. Chem. 2001;276:35552&#x2013;35557. doi: 10.1074/jbc.M106261200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M106261200</ArticleId><ArticleId IdType="pubmed">11463796</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen H.S., Diep T.A. N-acylethanolamines, anandamide and food intake. Biochem. Pharmacol. 2009;78:553&#x2013;560. doi: 10.1016/j.bcp.2009.04.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2009.04.024</ArticleId><ArticleId IdType="pubmed">19413995</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleberg K., Hassing H.A., Hansen H.S. Classical endocannabinoid-like compounds and their regulation by nutrients. Biofactors. 2014;40:363&#x2013;372. doi: 10.1002/biof.1158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/biof.1158</ArticleId><ArticleId IdType="pubmed">24677570</ArticleId></ArticleIdList></Reference><Reference><Citation>Aloe L., Leon A., Levi-Montalcini R. A proposed autacoid mechanism controlling mastocyte behaviour. Agents Actions. 1993;39:C145&#x2013;C147. doi: 10.1007/BF01972748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01972748</ArticleId><ArticleId IdType="pubmed">7505999</ArticleId></ArticleIdList></Reference><Reference><Citation>Facci L., Dal Toso R., Romanello S., Buriani A., Skaper S.D., Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. USA. 1995;92:3376&#x2013;3380. doi: 10.1073/pnas.92.8.3376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.92.8.3376</ArticleId><ArticleId IdType="pmc">PMC42169</ArticleId><ArticleId IdType="pubmed">7724569</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi-Montalcini R., Skaper S.D., Dal Toso R., Petrelli L., Leon A. Nerve growth factor: From neurotrophin to neurokine. Trends Neurosci. 1996;19:514&#x2013;520. doi: 10.1016/S0166-2236(96)10058-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0166-2236(96)10058-8</ArticleId><ArticleId IdType="pubmed">8931279</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Marzo V., Melck D., Orlando P., Bisogno T., Zagoory O., Bifulco M., Vogel Z., De Petrocellis L. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem. J. 2001;358:249&#x2013;255. doi: 10.1042/bj3580249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bj3580249</ArticleId><ArticleId IdType="pmc">PMC1222054</ArticleId><ArticleId IdType="pubmed">11485574</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrosino S., Schiano Moriello A., Verde R., Allar&#xe0; M., Imperatore R., Ligresti A., Mahmoud A.M., Peritore A.F., Iannotti F.A., Di Marzo V. Palmitoylethanolamide counteracts substance P-induced mast cell activation in vitro by stimulating diacylglycerol lipase activity. J. Neuroinflamm. 2019;16:274. doi: 10.1186/s12974-019-1671-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1671-5</ArticleId><ArticleId IdType="pmc">PMC6933707</ArticleId><ArticleId IdType="pubmed">31878942</ArticleId></ArticleIdList></Reference><Reference><Citation>Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., S&#xf8;rg&#xe5;rd M., Di Marzo V., Julius D., H&#xf6;gest&#xe4;tt E.D. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 1999;400:452&#x2013;457. doi: 10.1038/22761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/22761</ArticleId><ArticleId IdType="pubmed">10440374</ArticleId></ArticleIdList></Reference><Reference><Citation>De Petrocellis L., Davis J.B., Di Marzo V. Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett. 2001;506:253&#x2013;256. doi: 10.1016/S0014-5793(01)02934-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-5793(01)02934-9</ArticleId><ArticleId IdType="pubmed">11602256</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho W.-S.V., Barrett D.A., Randall M.D. &#x201c;Entourage&#x201d; effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. Br. J. Pharmacol. 2008;155:837&#x2013;846. doi: 10.1038/bjp.2008.324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bjp.2008.324</ArticleId><ArticleId IdType="pmc">PMC2597234</ArticleId><ArticleId IdType="pubmed">18695637</ArticleId></ArticleIdList></Reference><Reference><Citation>Zygmunt P.M., Ermund A., Movahed P., Andersson D.A., Simonsen C., J&#xf6;nsson B.A.G., Blomgren A., Birnir B., Bevan S., Eschalier A., et al. Monoacylglycerols activate TRPV1&#x2014;A link between phospholipase C and TRPV1. PLoS ONE. 2013;8:e81618. doi: 10.1371/journal.pone.0081618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0081618</ArticleId><ArticleId IdType="pmc">PMC3847081</ArticleId><ArticleId IdType="pubmed">24312564</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo Verme J., Fu J., Astarita G., La Rana G., Russo R., Calignano A., Piomelli D. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol. Pharmacol. 2005;67:15&#x2013;19. doi: 10.1124/mol.104.006353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.104.006353</ArticleId><ArticleId IdType="pubmed">15465922</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryberg E., Larsson N., Sj&#xf6;gren S., Hjorth S., Hermansson N.-O., Leonova J., Elebring T., Nilsson K., Drmota T., Greasley P.J. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 2007;152:1092&#x2013;1101. doi: 10.1038/sj.bjp.0707460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjp.0707460</ArticleId><ArticleId IdType="pmc">PMC2095107</ArticleId><ArticleId IdType="pubmed">17876302</ArticleId></ArticleIdList></Reference><Reference><Citation>Musella A., Fresegna D., Rizzo F.R., Gentile A., Bullitta S., De Vito F., Guadalupi L., Centonze D., Mandolesi G. A novel crosstalk within the endocannabinoid system controls GABA transmission in the striatum. Sci. Rep. 2017;7:7363. doi: 10.1038/s41598-017-07519-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-07519-8</ArticleId><ArticleId IdType="pmc">PMC5544685</ArticleId><ArticleId IdType="pubmed">28779174</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Shabat S., Fride E., Sheskin T., Tamiri T., Rhee M.H., Vogel Z., Bisogno T., De Petrocellis L., Di Marzo V., Mechoulam R. An entourage effect: Inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur. J. Pharmacol. 1998;353:23&#x2013;31. doi: 10.1016/S0014-2999(98)00392-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-2999(98)00392-6</ArticleId><ArticleId IdType="pubmed">9721036</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrosino P., Soldovieri M.V., Russo C., Taglialatela M. Activation and desensitization of TRPV1 channels in sensory neurons by the PPAR&#x3b1; agonist palmitoylethanolamide. Br. J. Pharmacol. 2013;168:1430&#x2013;1444. doi: 10.1111/bph.12029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.12029</ArticleId><ArticleId IdType="pmc">PMC3596648</ArticleId><ArticleId IdType="pubmed">23083124</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrosino P., Soldovieri M.V., De Maria M., Russo C., Taglialatela M. Functional and biochemical interaction between PPAR&#x3b1; receptors and TRPV1 channels: Potential role in PPAR&#x3b1; agonists-mediated analgesia. Pharmacol. Res. 2014;87:113&#x2013;122. doi: 10.1016/j.phrs.2014.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2014.06.015</ArticleId><ArticleId IdType="pubmed">25014183</ArticleId></ArticleIdList></Reference><Reference><Citation>Guida F., Luongo L., Boccella S., Giordano M.E., Romano R., Bellini G., Manzo I., Furiano A., Rizzo A., Imperatore R., et al. Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: Involvement of the CB2 receptor. Sci. Rep. 2017;7:375. doi: 10.1038/s41598-017-00342-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-00342-1</ArticleId><ArticleId IdType="pmc">PMC5428303</ArticleId><ArticleId IdType="pubmed">28336953</ArticleId></ArticleIdList></Reference><Reference><Citation>Scuderi C., Esposito G., Blasio A., Valenza M., Arietti P., Steardo L., Carnuccio R., De Filippis D., Petrosino S., Iuvone T., et al. Palmitoylethanolamide counteracts reactive astrogliosis induced by &#x3b2;-amyloid peptide. J. Cell. Mol. Med. 2011;15:2664&#x2013;2674. doi: 10.1111/j.1582-4934.2011.01267.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1582-4934.2011.01267.x</ArticleId><ArticleId IdType="pmc">PMC4373435</ArticleId><ArticleId IdType="pubmed">21255263</ArticleId></ArticleIdList></Reference><Reference><Citation>Scuderi C., Valenza M., Stecca C., Esposito G., Carrat&#xf9; M.R., Steardo L. Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator-activated receptor-&#x3b1;. J. Neuroinflamm. 2012;9:49. doi: 10.1186/1742-2094-9-49.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-9-49</ArticleId><ArticleId IdType="pmc">PMC3315437</ArticleId><ArticleId IdType="pubmed">22405189</ArticleId></ArticleIdList></Reference><Reference><Citation>Troncoso-Escudero P., Parra A., Nassif M., Vidal R.L. Outside in: Unraveling the Role of Neuroinflammation in the Progression of Parkinson&#x2019;s Disease. Front. Neurol. 2018;9:860. doi: 10.3389/fneur.2018.00860.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.00860</ArticleId><ArticleId IdType="pmc">PMC6232883</ArticleId><ArticleId IdType="pubmed">30459700</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Liu Y., Zhou J. Neuroinflammation in Parkinson&#x2019;s disease and its potential as therapeutic target. Transl. Neurodegener. 2015;4:19. doi: 10.1186/s40035-015-0042-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-015-0042-0</ArticleId><ArticleId IdType="pmc">PMC4603346</ArticleId><ArticleId IdType="pubmed">26464797</ArticleId></ArticleIdList></Reference><Reference><Citation>Tansey M.G., Goldberg M.S. Neuroinflammation in Parkinson&#x2019;s disease: Its role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis. 2010;37:510&#x2013;518. doi: 10.1016/j.nbd.2009.11.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2009.11.004</ArticleId><ArticleId IdType="pmc">PMC2823829</ArticleId><ArticleId IdType="pubmed">19913097</ArticleId></ArticleIdList></Reference><Reference><Citation>Guevara C., Ortiz F.C. Glial-derived transforming growth factor &#x3b2;1 (TGF-&#x3b2;1): A key factor in multiple sclerosis neuroinflammation. Neural Regen. Res. 2021;16:510&#x2013;511. doi: 10.4103/1673-5374.293147.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.293147</ArticleId><ArticleId IdType="pubmed">32985478</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellwardt E., Zipp F. Molecular mechanisms linking neuroinflammation and neurodegeneration in MS. Exp. Neurol. 2014;262 Pt A:8&#x2013;17. doi: 10.1016/j.expneurol.2014.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2014.02.006</ArticleId><ArticleId IdType="pubmed">24530639</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra P.-S., Vijayalakshmi K., Nalini A., Sathyaprabha T.N., Kramer B.W., Alladi P.A., Raju T.R. Etiogenic factors present in the cerebrospinal fluid from amyotrophic lateral sclerosis patients induce predominantly pro-inflammatory responses in microglia. J. Neuroinflamm. 2017;14:251. doi: 10.1186/s12974-017-1028-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-017-1028-x</ArticleId><ArticleId IdType="pmc">PMC5732516</ArticleId><ArticleId IdType="pubmed">29246232</ArticleId></ArticleIdList></Reference><Reference><Citation>Oeckl P., Weydt P., Steinacker P., Anderl-Straub S., Nordin F., Volk A.E., Diehl-Schmid J., Andersen P.M., Kornhuber J., Danek A., et al. Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. J. Neurol. Neurosurg. Psychiatry. 2019;90:4&#x2013;10. doi: 10.1136/jnnp-2018-318868.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318868</ArticleId><ArticleId IdType="pubmed">30224549</ArticleId></ArticleIdList></Reference><Reference><Citation>Masi A., Quintana D.S., Glozier N., Lloyd A.R., Hickie I.B., Guastella A.J. Cytokine aberrations in autism spectrum disorder: A systematic review and meta-analysis. Mol. Psychiatry. 2015;20:440&#x2013;446. doi: 10.1038/mp.2014.59.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2014.59</ArticleId><ArticleId IdType="pubmed">24934179</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Ansary A., Al-Ayadhi L. Neuroinflammation in autism spectrum disorders. J. Neuroinflamm. 2012;9:265. doi: 10.1186/1742-2094-9-265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-9-265</ArticleId><ArticleId IdType="pmc">PMC3549857</ArticleId><ArticleId IdType="pubmed">23231720</ArticleId></ArticleIdList></Reference><Reference><Citation>Torrado-Carvajal A., Toschi N., Albrecht D.S., Chang K., Akeju O., Kim M., Edwards R.R., Zhang Y., Hooker J.M., Duggento A., et al. Thalamic neuroinflammation as a reproducible and discriminating signature for chronic low back pain. Pain. 2020 doi: 10.1097/j.pain.0000000000002108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/j.pain.0000000000002108</ArticleId><ArticleId IdType="pubmed">33065737</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda M., Huh Y., Ji R.-R. Roles of Inflammation, Neurogenic inflammation, and Neuroinflammation in Pain. J. Anesth. 2019;33:131&#x2013;139. doi: 10.1007/s00540-018-2579-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00540-018-2579-4</ArticleId><ArticleId IdType="pmc">PMC6813778</ArticleId><ArticleId IdType="pubmed">30448975</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruccu G., Stefano G.D., Marchettini P., Truini A. Micronized Palmitoylethanolamide: A Post Hoc Analysis of a Controlled Study in Patients with Low Back Pain&#x2014;Sciatica. CNS Neurol. Disord. Drug Targets. 2019;18:491&#x2013;495. doi: 10.2174/1871527318666190703110036.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871527318666190703110036</ArticleId><ArticleId IdType="pmc">PMC7132032</ArticleId><ArticleId IdType="pubmed">31269891</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J., Xie H., Yao S., Liang Y. Macrophage and nerve interaction in endometriosis. J. Neuroinflamm. 2017;14:53. doi: 10.1186/s12974-017-0828-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-017-0828-3</ArticleId><ArticleId IdType="pmc">PMC5351283</ArticleId><ArticleId IdType="pubmed">28288663</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides T.C., Tsilioni I., Bawazeer M. Mast Cells, Neuroinflammation and Pain in Fibromyalgia Syndrome. Front. Cell. Neurosci. 2019;13:353. doi: 10.3389/fncel.2019.00353.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2019.00353</ArticleId><ArticleId IdType="pmc">PMC6687840</ArticleId><ArticleId IdType="pubmed">31427928</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryabkova V.A., Churilov L.P., Shoenfeld Y. Neuroimmunology: What Role for Autoimmunity, Neuroinflammation, and Small Fiber Neuropathy in Fibromyalgia, Chronic Fatigue Syndrome, and Adverse Events after Human Papillomavirus Vaccination? Int. J. Mol. Sci. 2019;20:5164. doi: 10.3390/ijms20205164.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20205164</ArticleId><ArticleId IdType="pmc">PMC6834318</ArticleId><ArticleId IdType="pubmed">31635218</ArticleId></ArticleIdList></Reference><Reference><Citation>Littlejohn G. Neurogenic neuroinflammation in fibromyalgia and complex regional pain syndrome. Nat. Rev. Rheumatol. 2015;11:639&#x2013;648. doi: 10.1038/nrrheum.2015.100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2015.100</ArticleId><ArticleId IdType="pubmed">26241184</ArticleId></ArticleIdList></Reference><Reference><Citation>Tauber S.C., Djukic M., Gossner J., Eiffert H., Br&#xfc;ck W., Nau R. Sepsis-associated encephalopathy and septic encephalitis: An update. Expert Rev. Anti-Infect. Ther. 2020:1&#x2013;17. doi: 10.1080/14787210.2020.1812384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14787210.2020.1812384</ArticleId><ArticleId IdType="pubmed">32808580</ArticleId></ArticleIdList></Reference><Reference><Citation>Heide E.C., Bindila L., Post J.M., Malzahn D., Lutz B., Seele J., Nau R., Ribes S. Prophylactic Palmitoylethanolamide Prolongs Survival and Decreases Detrimental Inflammation in Aged Mice with Bacterial Meningitis. Front. Immunol. 2018;9:2671. doi: 10.3389/fimmu.2018.02671.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02671</ArticleId><ArticleId IdType="pmc">PMC6250830</ArticleId><ArticleId IdType="pubmed">30505308</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerner R., Pascual Cuadrado D., Post J.M., Lutz B., Bindila L. Broad Lipidomic and Transcriptional Changes of Prophylactic PEA Administration in Adult Mice. Front. Neurosci. 2019;13:527. doi: 10.3389/fnins.2019.00527.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00527</ArticleId><ArticleId IdType="pmc">PMC6580993</ArticleId><ArticleId IdType="pubmed">31244590</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>